Clinical Trial

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Study acronym: SECuRE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2021-04-27; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Recruiting 2021-08-09
Trial Details
NCT Number NCT04868604
Lead Sponsor Clarity Pharmaceuticals Ltd
Conditions Prostatic Neoplasms, Castration-Resistant
Enrollment 54 participants
Start Date 2021-08-11
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-06